SCHEMBL19656294

SCHEMBL19656294

COC(=O)Cn1cc(-c2ccc(B3OC(C)(C)C(C)(C)O3)cc2)cn1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.43
LIPG Q9Y5X9 9/20 0.43
LPL P06858 8/20 0.43
DGAT1 O75907 1/20 0.42
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
FAAH O00519 1/20 0.38
CCNC P24863 2/20 0.38
CDK8 P49336 2/20 0.38
SYK P43405 1/20 0.36
FLT3 P36888 1/20 0.35
MYLK Q15746 1/20 0.35
AURKB Q96GD4 1/20 0.35
CILK1 Q9UPZ9 1/20 0.35
CDK11A Q9UQ88 1/20 0.35
MAP4K4 O95819 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25414529 0.88 FFAR1 (0.46) FFAR1LIPGLPLDGAT1KEAP1
SCHEMBL22448097 0.87 FFAR1 (0.46) FFAR1LIPGLPLDGAT1KEAP1
SCHEMBL4099087 0.86 FFAR1 (0.57) FFAR1LIPGLPLDGAT1FAAH
SCHEMBL21392525 0.84 ROCK1 (0.40) FFAR1LIPGLPLDGAT1FAAH
SCHEMBL19656319 0.84 CCNC (0.52) FFAR1LIPGLPLCCNCCDK8
SCHEMBL22448098 0.80 FFAR1 (0.44) FFAR1LIPGLPLDGAT1KEAP1
SCHEMBL15661307 0.80 LIPG (0.51) FFAR1LIPGLPLDGAT1
SCHEMBL17437195 0.80 LPL (0.46) FFAR1LIPGLPLDGAT1
SCHEMBL19656293 0.77 KCNH2 (0.48) FAAHCCNCCDK8SYKFLT3
SCHEMBL15299283 0.77 FFAR1 (0.74) FFAR1LIPGLPLCCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11213520-B2 Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-01-04 US disclosed
EP-3464267-B1 NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2020-09-23 EP disclosed
US-20190290637-A1 NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-09-26 US disclosed
WO-2017202719-A1 NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11213520-B2 Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors CDK9, CDK19, CDK8 FFAR1 4806/4885LIPG 4695/4885LPL 4824/4885
US-20190290637-A1 NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS CDK9, CDK19, CDK8 FFAR1 4790/4885LIPG 4758/4885LPL 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.